Early tumor shrinkage and depth of response during treatment with immune checkpoint inhibitors as predictors of overall survival in patients receiving second-line or later therapy for advanced esophageal squamous cell carcinoma: a retrospective study

Early tumor shrinkage (ETS) and depth of response (DoR) reflect tumor response heterogeneity and may predict immunotherapy outcomes. This study evaluated the prognostic values of ETS and DoR in patients with advanced esophageal squamous cell carcinoma (ESCC) who received second-line or later immune checkpoint inhibitor (ICI) therapy. We retrospectively analyzed 121 patients with advanced/metastatic ESCC who received ICI therapy after treatment failure. ETS (at 8 weeks) and DoR (maximal shrinkage) were assessed using Response Evaluation Criteria in Solid Tumors version 1.1. Associations with overall survival (OS) were evaluated using Kaplan–Meier and Cox regression analyses. Longer OS was significantly associated with achieving ETS ≥ 10% ( p < 0.05) and DoR ≥ 13% ( p < 0.05), as well as with the absence of lymphatic metastasis ( p < 0.05). In multivariate analysis, DoR ≥ 13% (hazard ratio [HR] = 2.44; 95% confidence interval [CI] 1.32–4.52; p = 0.005) and lymphatic metastasis (HR = 0.49; 95% CI 0.27–0.89; p = 0.020) were independent prognostic factors for OS. Notably, patients who achieved both high ETS and deep DoR (optimal responders) had the most favorable survival outcomes, whereas those achieving neither had the poorest survival (log-rank p < 0.001), demonstrating that ETS and DoR provide complementary prognostic information. DoR is an independent determinant of survival in patients with advanced ESCC treated with later-line ICIs. Early tumor shrinkage provides synergistic prognostic information. Their combined assessment offers a refined stratification tool to guide clinical decision-making. This study was approved by the Institutional Review Board of the First Affiliated Hospital of Zhengzhou University (No. 2025-KY-0988-002). All patients signed an informed consent form before the examination.

Authors

Institutions

Publication Details

Journal
Cancer Imaging
Published
2026-09-12
DOI
https://doi.org/10.1186/s40644-026-01127-4
Primary Topic
Esophageal Cancer Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Early tumor shrinkage and depth of response during treatment with immune checkpoint inhibitors as predictors of overall survival in patients receiving second-line or later therapy for advanced esophageal squamous cell carcinoma: a retrospective study

Yue Zhou, Jingjing Xing, Xiangrui Meng, Feng Wang et al.
Cancer Imaging
Esophageal Cancer Research and Treatment
article

Early tumor shrinkage and depth of response during treatment with immune checkpoint inhibitors as predictors of overall survival in patients receiving second-line or later therapy for advanced esophageal squamous cell carcinoma: a retrospective study

Yue Zhou, Jingjing Xing, Xiangrui Meng, Feng Wang, Mingyue Wang, Jianbo Gao
article en

Abstract

Early tumor shrinkage (ETS) and depth of response (DoR) reflect tumor response heterogeneity and may predict immunotherapy outcomes. This study evaluated the prognostic values of ETS and DoR in patients with advanced esophageal squamous cell carcinoma (ESCC) who received second-line or later immune checkpoint inhibitor (ICI) therapy. We retrospectively analyzed 121 patients with advanced/metastatic ESCC who received ICI therapy after treatment failure. ETS (at 8 weeks) and DoR (maximal shrinkage) were assessed using Response Evaluation Criteria in Solid Tumors version 1.1. Associations with overall survival (OS) were evaluated using Kaplan–Meier and Cox regression analyses. Longer OS was significantly associated with achieving ETS ≥ 10% ( p < 0.05) and DoR ≥ 13% ( p < 0.05), as well as with the absence of lymphatic metastasis ( p < 0.05). In multivariate analysis, DoR ≥ 13% (hazard ratio [HR] = 2.44; 95% confidence interval [CI] 1.32–4.52; p = 0.005) and lymphatic metastasis (HR = 0.49; 95% CI 0.27–0.89; p = 0.020) were independent prognostic factors for OS. Notably, patients who achieved both high ETS and deep DoR (optimal responders) had the most favorable survival outcomes, whereas those achieving neither had the poorest survival (log-rank p < 0.001), demonstrating that ETS and DoR provide complementary prognostic information. DoR is an independent determinant of survival in patients with advanced ESCC treated with later-line ICIs. Early tumor shrinkage provides synergistic prognostic information. Their combined assessment offers a refined stratification tool to guide clinical decision-making. This study was approved by the Institutional Review Board of the First Affiliated Hospital of Zhengzhou University (No. 2025-KY-0988-002). All patients signed an informed consent form before the examination.

Cancer Imaging
First Affiliated Hospital of Zhengzhou University (CN)
Openalex Percentile: Top 8%
Esophageal Cancer Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.